Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.31 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408912 | 1.00 | LPL (0.39) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL2409526 | 0.82 | LPL (0.43) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL2406488 | 0.81 | IDO1 (0.38) | CA2CA1KMT2AHTT | |
| SCHEMBL2406493 | 0.81 | IDO1 (0.38) | CA2CA1KMT2AHTT | |
| SCHEMBL13978537 | 0.69 | LPL (0.59) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL509011 | 0.69 | CA1 (0.57) | CA2CA1KMT2AHTT | |
| SCHEMBL28884382 | 0.68 | TSHR (0.41) | CA2CA1KMT2A | |
| SCHEMBL28884380 | 0.68 | TSHR (0.41) | CA2CA1KMT2A | |
| SCHEMBL17298142 | 0.68 | LPL (0.64) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL24680587 | 0.68 | LPL (0.52) | LPLLIPGCA2CA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2212317-A1 | 4,4-DISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053452-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | LPL 2373/4885LIPG 1550/4885CA2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.